Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (10): 80-85.doi: 10.6040/j.issn.1671-7554.0.2019.104

Previous Articles     Next Articles

Establishment of survival related multigene prognostic model of epithelial ovarian cancer

ZHU Aiguo, MA Zhenchi, WANG Jian   

  1. Department of Comprehensive Surgery, Tianjin Medical University Cancer Institute and Hospital;
    National Clinical Research Center for Cancer;
    Key Laboratory of Cancer Prevention and Therapy, Tianjin;
    Tianjins Clinical Research Center for Cancer, Tianjin 300060, China
  • Published:2022-09-27

PDF (PC)

267

Abstract: Objective To establish a multigene prognostic model associated with the prognosis of the epithelial ovarian cancer(EOC)patients and validate the prognostic power through Gene Expression Omnibus(GEO)database and The Cancer Genome Atlas(TCGA)database. Methods The Affymetrix expression profiles(GSE14407)were downloaded 山 东 大 学 学 报 (医 学 版)57卷10期 -朱爱国,等.利用上皮源性卵巢癌预后的多基因信息建立预测预后模型 \=-and analyzed from GEO dataset. Different expression genes(DEGs)between EOC tissue and normal epithelial tissue were selected to identify a multigene prognostic model. DEGs were selected by univariate and multivariate Cox regression model to establish a multigene prognostic model and prognostic index(PI)formula. mRNA expression data and clinical data of patients were obtained from TCGA dataset. According to PI, the patients were divided into high risk group and low risk group. Clinical and pathological feature(age, neoplasm subdivision, histologic grade, residual tumor, clinical stage)and PI were evaluated as influence factors affecting overall survival(OS)of EOC patients. The prognostic value of multigene model by Kaplan-Meier survival analysis was verified in overall and subgroup EOC patients according to age, neoplasm subdivision, residual tumor, and clinical stage. Results A total of 47 DEGs between EOC and normal tissues were screened, in which 37 DEGs were down-regulated and 17 DEGs were up-regulated. By univariate and multivariate Cox model, 4DEGs, i.e., PACSIN3,KCNT1,LAMP3 and KIR3DX1, were finally selected to establish a four-gene prognostic model. PI formula was as follows:(-0.169 × the expression of PACSIN3 + 0.078 × the expression of KCNT1 -0.246 × the expression of LAMP3 -0.147 × the expression of KIR3DX1). Age, residual tumor and multigene gene prognostic model were independent prognostic factors of EOC patients(P<0.01). OS of low risk group was longer than high risk group by K-M plots(P<0.05). In different subgroups(age,clinical stage, neoplasm subdivision, residual tumor)of EOC patients, low risk group had longer OS than high risk group(P<0.05). Conclusion Four-gene prognostic model is the independent prognostic factor in EOC patients, and is demonstrated remarkable prognostic value in overall EOC patients and each subgroup according to different clinical and pathological factors.

Key words: Ovary cancer, Prognosis, The Cancer Genome Atlas, Cox proportional regression model, Biological information

CLC Number: 

  • R711.75
[1] 陈静, 李春艳, 赵苗青, 等. EZH2蛋白在卵巢上皮性肿瘤中的表达及其作用[J]. 山东大学学报(医学版), 2015, 53(2): 65-70. CHEN Jing, LI Chunyan, ZHAO Miaoqing, et al. Expression of EZH2 protein and its role in ovarian epithelial tumor [J]. Journal of Shandong University(Health Sciences), 2015, 53(2): 65-70.
[2] Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: current status and future promise[J]. Gynecol Oncol, 2014, 133(2): 362-369.
[3] Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer[J]. Ann Oncol, 2017, 28(suppl_8): viii61-viii65.
[4] Ramalingam P. Morphologic, immunophenotypic, and molecular features of epithelial ovarian cancer[J]. Oncology(Williston Park), 2016, 30(2): 166-176.
[5] 邱建,傅云峰,周彩云,等. 上皮性卵巢癌组织CK2β和p53蛋白表达临床意义分析[J].中华肿瘤防治杂志, 2015,22(6): 451-456. QIU Jian, FU Yunfeng, ZHOU Caiyun, et al. Analysis of the relationship between expression of CK2β, p53 and prognosis in epithelial ovarian cancer tissues[J]. Chin J Cancer Prev Treat, 2015, 22(6): 451-456.
[6] Nakonechny QB, Gilks CB. Ovarian cancer in hereditary cancer susceptibility syndromes[J]. Surg Pathol Clin, 2016, 9(2): 189-199.
[7] Zhang M, Zhuang G, Sun X, et al. TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer[J]. Diagn Pathol, 2017, 12(1):16. doi: 10.1186/s13000-017-0605-8.
[8] Darcy KM, Brady WE, Mcbroom JW, et al. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study[J]. Gynecol Oncol, 2008, 111(3): 487-495.
[9] Seagle BLL, Yang CPH, Eng KH, et al. TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas[J]. Gynecol Oncol, 2015, 138(1): 159-164.
[10] Kotsopoulos J, Rosen B, Fan I, et al. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status[J]. Gynecol Oncol, 2016, 140(1): 42-47.
[11] Arts-de Jong M, de Bock GH, van Asperen CJ, et al. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review[J]. Eur J Cancer, 2016, 61:137-145. doi: 10.1016/j.ejca.2016.03.009.
[12] Dumas J, Gargano MA, Dancik GM. shinyGEO: a web-based application for analyzing Gene Expression Omnibus datasets[J]. Bioinformatics, 2016, 32(23): 3679-3681.
[13] Colaprico A, Silva TC, Olsen C, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data[J]. Nucleic Acids Res, 2016, 44(8): e71. doi: 10.1093/nar/gkv1507.
[14] Zhou W, Ma C, Yan Z. Microarray data analysis reveals differentially expressed genes in prolactinoma[J]. Neoplasma, 2015, 62(1): 53-60.
[15] 毛燕南, 曾丽霞, 李宇虹, 等. PAX8、PAX2、p53和RAS蛋白在卵巢及输卵管组织中的表达对于高级别卵巢浆液性癌起源的意义[J]. 中华妇产科杂志, 2017, 52(10): 687-696. MAO Yannan, ZENG Lixia, LI Yuhong, et al. Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma[J]. Zhonghua Fu Chan Ke Za Zhi, 2017, 52(10): 687-696.
[16] Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2017, 4: 3-14. doi: 10.1016/j.bpobgyn.2016.08.006.
[17] Andrews L, Mutch DG. Hereditary ovarian cancer and risk reduction[J]. Best Pract Res Clin Obstet Gynaecol, 2017, 4: 31-48. doi: 10.1016/j.bpobgyn.2016.10.017.
[18] Graffeo R, Livraghi L, Pagani O, et al. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care[J]. Breast Cancer Res Tr, 2016, 160(3): 393-410.
[19] Schael S, Nuchel J, Muller S, et al. Casein kinase 2 phosphorylation of protein kinase C and casein kinase 2 substrate in neurons(PACSIN)1 protein regulates neuronal spine formation[J]. J Biol Chem, 2013, 288(13): 9303-9312.
[20] Roach W, Plomann M. PACSIN3 overexpression increases adipocyte glucose transport through GLUT1[J]. Biochem Biophys Res Commun, 2007, 355(3): 745-750.
[21] Lim CX, Ricos MG, Dibbens LM, et al. KCNT1 mutations in seizure disorders: the phenotypic spectrum and functional effects[J]. J Med Genet, 2016, 53(4): 217-225.
[22] Rizzo F, Ambrosino P, Guacci A, et al. Characterization of two De novo Kcnt1 mutations in children with malignant migrating partial seizures in infancy[J]. Mol Cell Neurosci, 2016, 72: 54-63. doi: 10.1016/j.mcn.2016.01.004.
[23] Nagelkerke A, Sieuwerts AM, Bussink J, et al. LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy[J]. Endocr Relat Cancer, 2013, 21(1): 101-112.
[24] Liao X, Chen Y, Liu D, et al. High expression of LAMP3 is a novel biomarker of poor prognosis in patients with esophageal squamous cell carcinoma[J]. Int J Mol Sci, 2015, 16(8): 17655-17667.
[25] Qiu X, You Y, Huang J, et al. LAMP3 and TP53 overexpression predicts poor outcome in laryngeal squamous cell carcinoma[J]. Int J Clin Exp Pathol, 2015, 8(5): 5519-5527.
[1] LI Ziqi, WEI Yanruoxue, LIU Xiaohan, LIU Chuncheng, ZHAO Ran, LIU Yukun. The functional role and clinical significance of lncRNA HEATR3-AS1 in colorectal cancer tumorigenesis and progression [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 108-115.
[2] LIU Baoguo, SONG Xiang, ZHAO Xiaowen, MAO Yali. Application value of serum STAT5B and NKAIN1 mRNA detection in breast cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(7): 68-74.
[3] WANG Lei, CHANG Xiao, WANG Zimeng, LI Jiaojiao, CUI Shujun, YANG Fei, ZHU Yuexiang. Predictive value of intratumoral and peritumoral DCE-MRI imaging histology for progression-free survival in patients with cervical cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 45-54.
[4] JIA Ruoxi, LYU Li, LIU Hanyun, WU Yinping, LI Fengcai, ZHAO Zehua, WANG Kai, FAN Yuchen. Diagnostic value of blood cell count-related biomarkers in predicting 28-day mortality in acute-on-chronic hepatitis b liver failure [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 89-99.
[5] DU Xue, LI Chunxia, LIU Yunxia, ZHANG Tao. Dynamic prediction model for the colorectal cancer patients prognosis based on MFPC-Cox [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 101-110.
[6] YANG Weifang, XU Hong, LIU Yuantao, ZHAO Huichen. Mechanism of thyroid-stimulating immunoglobulin in Graves disease recurrence and clinical significance [J]. Journal of Shandong University (Health Sciences), 2025, 63(4): 116-121.
[7] LIU Wenzhao, ZHANG Yuan, MA Xiangping, WEI Fengtao, BU Peili. Correlation between the pre-endothelial activation and stress index and the mortality risk of patients with heart failure [J]. Journal of Shandong University (Health Sciences), 2025, 63(11): 27-35.
[8] CHEN Wenliang, WANG Huanhuan, HAO Jinjin, GONG Rui, ZHAO Qiang, ZHANG Fei, GAO Lei, DONG Jingxun. The role of lncRNA PVT1 in prognostic assessment and malignant progression of gastric cancer: a study based on nomogram model and functional cellular experiments [J]. Journal of Shandong University (Health Sciences), 2025, 63(10): 61-71.
[9] GUO Shuhua, FAN Yang, TIAN Feng, WANG Chuanxin, DU Lutao, LI Peilong, GUO Xing, XU Shuo. Role of microfibril-associated protein 3 in regulating mesenchymal transition of glioma stem cells [J]. Journal of Shandong University (Health Sciences), 2024, 62(6): 9-16.
[10] WEI Yanruoxue, LI Ziqi, LIU Chuncheng, LIU Xiaohan, ZHAO Ran, LIU Yukun. Intratumor heterogeneity of SP1 expression in colorectal cancer and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2024, 62(5): 89-94.
[11] LIU Chuncheng, LIU Xiaohan, WEI Yanruoxue, LI Ziqi, LIU Yukun, ZHAO Ran. Subcellular localization pattern of bromodomain containing 9 in colorectal cancer and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2024, 62(4): 24-30.
[12] YANG Xueyan, WU Yinping, LYU Li, ZHAO Zehua, MA Hangyu, LI Fengcai, WANG Kai, FAN Yuchen. Diagnostic value of dynamic changes of monocyte-to-lymphocyte ratio in acute-on-chronic hepatitis B liver failure [J]. Journal of Shandong University (Health Sciences), 2024, 62(3): 61-69.
[13] DIAO Yujie, LIN Lin, LI Wenxuan, WANG Zhouyang, JIANG Bei, HU Yingying, LIU Guangyi. Neutrophil-to-platelet ratio predicts adverse renal outcomes in anti-neutrophil cytoplasmic antibody-associated vasculitis and its synergistic multifactor optimization model [J]. Journal of Shandong University (Health Sciences), 2024, 62(2): 60-68.
[14] MENG Jianli, WANG Qinggang. Expression and potential mechanism of VPS72 in lung adenocarcinoma/ squamous cell carcinoma by integrated bioinformatics analysis [J]. Journal of Shandong University (Health Sciences), 2023, 61(8): 40-49.
[15] LIU Yan, LENG Shanshan, XIA Xiaona, DONG Hao, HUANG Chencui, MENG Xiangshui. Functional outcomes of 376 patients with supratentorial spontaneous intracerebral hemorrhage based on radiomic parameters [J]. Journal of Shandong University (Health Sciences), 2023, 61(5): 59-67.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd